secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001558370-22-017292
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics reports Q3 net loss of $35.8M; ublituximab PDUFA set for Dec 28, 2022
--------------------------------------------------------------------------------

- Net loss of $35.8M for Q3 2022 vs $85.6M in Q3 2021; nine-month net loss of $145.3M.
- Cash, equivalents and securities totaled $197.7M as of Sept 30, 2022; funding expected into 2024.
- R&D expense fell to $20.8M from $52.0M; SG&A decreased to $14.3M from $34.9M YoY.
- Ublituximab BLA for relapsing MS has PDUFA goal date of December 28, 2022; commercial prep ongoing.
- Company plans to launch ublituximab early 2023 if FDA approves.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/0001558370-22-017292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/tgtx-20221110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer